This article is more than 5 years old. Information may no longer be current.

Glaucoma implant proceeds to phase 3 trials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — The Food and Drug Administration has cleared GMP Companies Inc. to initiate a phase 3 clinical trial of its Eyepass glaucoma implant.

According to the company, the study will establish the safety and effectiveness of the implant in patients with glaucoma who have not responded to conventional medical and surgical treatments.

The trial is being conducted by GMP Vision Solutions Inc., a subsidiary of GMP Companies. Enrollment has been initiated, with the company planning to involve up to 15 investigational sites in the United States.